

Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:

Dr Eron has served as an ad hoc consultant to Janssen, ViiV Healthcare, Merck & Co, Inc, and Gilead Sciences, Inc. His institution receives contracts for clinical research on which Dr Eron is the local principal investigator from Janssen Therapeutics, ViiV Healthcare, and Gilead Sciences, Inc. (Updated 03/22/21)

Slide

2

Learning Objectives

Upon completion of this webinar, learners will be able to:

- Describe why new antiretrovirals are still needed for the treatment and prevention of HIV-1
- List at least 2 new long-acting antiretroviral treatment strategies
 that are in development

Goals of Antiretroviral Therapy

•Maintain or restore the health of people living with HIV-1 (PWH) through suppression of HIV-1 replication

•Minimize or eliminate short and long-term adverse effects of the therapy

-Have therapies that are accessible to all PWH

•Prevent transmission of HIV-1 to others via any route of exposure



6

Why Do We Need New Agents?

What we have now

- Oral therapy Multiple single tablet daily regimens
 Many without lood restrictions, several with almost no DDI
 Few frequent AE (weight gain?), rare serious AE (? DM, massive weight gain)
 INSTI based and Ph-based therapy almost resistance proof
 Relatively simple therapy for PWH with resistant virus if suppressed on therapy w/o INSTI
 resistance resistance

. Long-acting injectable therapy with CAB/RPV

- Non-inferior to gold-standard oral therapy in PWH suppressed without previous virologic failure
- Twice monthly IM Injection and no need for oral lead-in (SOLAR and others)
- Clear interest for many PWH
- Social behavioral, QoL and internal and external stigma benefits for many who choose LA Potential to extend our reach to hardly engaged populations (USCF experience)

7

Why Do We Need New Agents?

Liabilities of current therapy and what we need


- Oral therapy
- An alternative to daily oral therapy (weekly or monthly?) A convenient, safe, resistance-resistant oral therapy without an INSTI or booster? Simpler and less complex therapy for PWH with MDR INSTI resistant HIV; whether rebounding or suppressed
- Long-acting therapy


 - No resistance risk with on-time administration More convenient delivery allowing home or non-office administration Broad inclusion previous virologic failure, current viremia, adolescents, children, pregnant people
 - Longer acting Affordable and scalable

New Agents Recently Approved




- First in class capsid inhibitor Oral loading followed by two SQ injections every 6 months Approved for heavily treatment-experienced PWH whose HIV cannot be successfully treated with other available treatments due to resistance,
- available treatments due to resistance intolerance, or safety considerations. No current long-acting partner agents Resistance emergence has been observed especially if oral agents have limited activity or adherence challenges







9


































16





Next Steps 0

LONG-ACTING THERAPY

18

Long-Acting Therapy – Partners needed Cabotegravir

- IM injections in the thigh
 - ATLAS 2M optional thigh injection study in 121 participants
- Both 1 monthly and 2 monthly Similar PK profiles when transitioning for IM gluteal injections .
- Cabotegravir plus VRC-07 523 LS
- Suppressed switch study

 - CAB LA q 4 week, VRC-07 q 8 week 75 enrolled 48 week follow-up ends 2nd QTR 2023 https://clinicaltrials.gov/ct2/show/NCT03739996



- CAB plus N6-LS planned
 - N6 slightly broader prolife and likely longer ½ life


19


Long-Acting Therapy – Partners Needed


- Lenacapravir Phase II study Treatment Naïve patients
 - Initiate with oral then SQ lenacapravir plus F/TAF (oral) for 28 weeks Week 28 second SQ LCV and either TAF or Bictegravir (2 drug therapy)
- Lenacapravir Phase Ib Treatment experienced suppressed
 - Oral then SQ lenacapravir plus Two long-acting monoclonal antibodies
 - . GS-5423 (3BNC117-LS) and GS-2872 (10-1074-LS)


 - Every 6 months 50 patients
 <u>https://clinicaltrials.gov/ct2/show/NCT04811040</u>
























25











Whv	Do V	Ve N	eed N	lew A	gents?

Summary

- The needs for new oral therapy are limited
- Less frequent dosing (e.g. weekly or monthly) may be appealing to many PWH
- Once daily oral therapies will have very high bar to replace current options
 Motivation for new drug development may wane
- Long-acting therapy is the new frontier Longer intervals may be the first hurdle to be overcome Partners to lenacapavir are hard to come by and barrier to resistance is unproven
 - May be more cumbersome or require susceptibility testing to start bNAb, while promising, many questions remain about susceptibility feasibility, cost, manufacture
- Novel delivery mechanism for small molecules may provide one answer

28

